Rhumbline Advisers Chemomab Therapeutics Ltd. Transaction History

Rhumbline Advisers

  • $113 Billion
  • Q2 2025

A detailed history of Rhumbline Advisers transactions in Chemomab Therapeutics Ltd. stock. As of the latest transaction made, Rhumbline Advisers holds 39,875 shares of CMMB stock, worth $121,220. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,875
Previous 23,849 67.2%
Holding current value
$121,220
Previous $25,000 84.0%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$0.94 - $1.42 $15,064 - $22,756
16,026 Added 67.2%
39,875 $46,000
Q1 2025

Apr 08, 2025
BUY
$1.09 - $2.44 $44 - $100
41 Added 0.17%
23,849 $26,000
Q4 2024

May 29, 2025
SELL
$1.13 - $2.02 $46 - $82
-41 Reduced 0.17%
23,808 $48,000
Q4 2024

Jan 30, 2025
SELL
$1.13 - $2.02 $4,254 - $7,605
-3,765 Reduced 13.65%
23,808 $48,000
Q3 2024

Nov 12, 2024
BUY
$0.93 - $2.46 $7,157 - $18,932
7,696 Added 38.72%
27,573 $43,000
Q2 2024

Aug 01, 2024
BUY
$0.59 - $1.29 $737 - $1,612
1,250 Added 6.71%
19,877 $18,000
Q4 2023

Feb 08, 2024
BUY
$0.45 - $0.9 $7,102 - $14,205
15,784 Added 555.19%
18,627 $9,000
Q3 2023

Nov 09, 2023
SELL
$0.9 - $1.42 $145 - $230
-162 Reduced 5.39%
2,843 $2,000
Q2 2023

Aug 08, 2023
BUY
$1.0 - $1.84 $3,005 - $5,529
3,005 New
3,005 $3,000

Others Institutions Holding CMMB

# of Institutions
13
Shares Held
4.21M
Call Options Held
0
Put Options Held
0
View Full List

About Chemomab Therapeutics Ltd.

CMMB Quotes by TradingView
  • Ticker CMMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,431,700
  • Market Cap $34.8M
  • Description
  • Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...
More about CMMB
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email